Sponsor: Janssen
Sponsor Study ID: EMN30/MajesTEC-4
Study Title: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
CTO #: 104178
NCT Number: NCT05243797
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Multiple Myeloma
Study Objectives: The primary objective of this study is to compare the efficacy of teclistamab in combination with lenalidomide with that of lenalidomide monotherapy and the efficacy of teclistamab monotherapy with that of lenalidomide monotherapy in the maintenance of setting, as assessed by PFS and 12-month MRD-negative CR.